With an uptick in licensing deals and promising data emerging from China-based biopharmas, especially in oncology, it’s clear ...

Sarepta would need to conduct new analyses to validate the safety of Elevidys—which has had U.S. shipments paused by the ...

Just as new outbreaks of chikungunya threaten to become another epidemic, Bavarian Nordic, maker of a vaccine against the ...

With tariffs looming and pricing policies shifting, life sciences companies may be on the cusp of “pivotal moment,” according ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic versions of Novo Nordisk’s lucrative semaglutide drugs for diabetes and obesi | ...

A direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit managers.

A soon-to-be-released documentary film aims to change the conversation around hemophilia, a condition in which many female ...

Secretary Robert F. Kennedy Jr. | HHS Secretary Robert F. Kennedy Jr. has signed off on a recommendation from an advisory ...

With the threat of tariffs looming for medicines imported to the United States, AstraZeneca has unveiled a plan to invest $50 ...

Ahead of the 10-year anniversary of Tagrisso’s initial FDA approval this fall, AstraZeneca has debuted the first ...

For many contract manufacturers, the end of the COVID-19 pandemic—and the production contracts that came with it—marked a ...

AbbVie and its subsidiary Allergan have had a long run of unchallenged success in the market with cosmetic and therapeutic ...